US Bancorp
PGNX

US Bancorp’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

US Bancorp’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-300
Closed -$2K – 3894
2019
Q4 		$2K Hold
300
– – ﹤0.01% 3531
2019
Q3 		$2K Hold
300
– – ﹤0.01% 3462
2019
Q2 		$2K Hold
300
– – ﹤0.01% 3508
2019
Q1 		$1K Hold
300
– – ﹤0.01% 3554
2018
Q4 		$1K Buy
+300
New +$1.53K ﹤0.01% 3556

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

US Bancorp's PGNX Position: Q1 2020 in Review

US Bancorp sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 300 shares — an estimated $2K sold.

US Bancorp first reported a position in PGNX in Q4 2018 and held it in 5 quarters. The position peaked at $2K in Q4 2019. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • US Bancorp reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • US Bancorp sold 300 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $2K.
  • US Bancorp first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 5 quarters.
  • US Bancorp's Progenics Pharmaceuticals Inc position peaked at $2K in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on US Bancorp's 13F filing for Q1 2020, filed 13 May 2020.